glp 1 agonist new Trends in the Development of GLP-1 Receptor Agonists Upcoming wave of hormone-based therapies
Description
Angelidi, A
The present recommendations of the American and European Diabetes Associations are currently updating their actual recommendation for the treatment algorithm for T2D ( Tirzepatide may also become an important pharmacological tool for the treatment of obesity if data from the SURMOUNT-1 trial are confirmed in other clinical studies (82)
The study appeared in Cancer Investigation on Nov
Ueda P, Soderling J, Wintzell V, Svanstrom H, Pazzagli L, Eliasson B, et al
Clinical evidence (based on the literature) on GLP-1 RAs licensed in South Asia or under regulatory approval in one or more South Asian countries is presented and based on prescription pattern and the geography of the reported patient group
In healthy humans, GIP-mediated elevation of circulating glucagon concentrations has also been observed
